Finacea Foam back on market after manufacturing delay

Finacea Foam, the only prescription foam approved by the FDA for the treatment of rosacea, is now available in the United States after a manufacturing delay that started in 2019, Leo Pharma announced in a press release.

Finacea Foam (azelaic acid 15%) is an alcohol- and fragrance-free hydrophilic foam.

A manufacturing delay suspended product supply in mid-2019; however, the supply has now been restored, the release said.

“We are pleased to bring Finacea Foam back on the market as an option for health care providers and their patients in the treatment and management of mild to moderate rosacea,” Christopher Posner, Leo Pharma president and CEO, said in the release. “People affected by rosacea are challenged by a chronic condition that affects the face, with symptoms including raised spots and pimple-like bumps. Helping patients is our mission at Leo Pharma, and we remain committed to supporting the medical dermatology community.”